|
GREG
KINNEAR JOINS STAND UP TO CANCER
AND LILLY ONCOLOGY IN NEW COLORECTAL CANCER PSA
New
Campaign Reinforces Patient Empowerment and Importance of
Personalized Tumor Genetic and Molecular Profiling in
Treatment of Colorectal Cancer
(LOS
ANGELES / NEW YORK) – Feb.
18, 2016 –
Stand Up To Cancer (SU2C), a program of the Entertainment
Industry Foundation (EIF), has teamed up with Eli Lilly and
Company on a new colorectal cancer public service
announcement (PSA) featuring actor and SU2C Ambassador Greg
Kinnear. The PSA will begin airing in March during National
Colorectal Cancer Awareness Month.
The PSA, entitled “You Are Your Most Powerful
Advocate,” is designed to raise awareness about the
importance of patient empowerment and knowledge of
personalized colorectal cancer treatments matched to the
genetic and molecular makeup of the patient’s tumor.
According to the Centers for Disease Control
and Prevention (CDC), colorectal cancer (cancer of the colon
or rectum) is the second leading cancer killer of men and
women combined, and the third most common form of cancer in
the United States. In 2016, about 135,000 people in the U.S.
will be diagnosed with colorectal cancer, and it will claim
the lives of almost 50,000.
The PSA encourages colorectal cancer patients
to visit standup2cancer.org/colorectalcancer to
learn more about how testing for the genetic and molecular
characteristics of their own individual colorectal cancer,
may help patients with their doctors select safer, more
effective treatment.
The PSA, featuring Kinnear looking directly
at the viewer, encourages colorectal cancer patients to seek
personalized information about their tumors, stating,
“Research shows that knowing the genetic and molecular
makeup of your colorectal tumor may lead to safer, more
effective treatment, just for you.”
“When my late husband Jay was diagnosed with
colorectal cancer more than 18 years ago, the first-line
treatment was the same drug that had been used since the
1950s, which was so frustrating,” added SU2C co-founder
Katie Couric. “There are better options now, so making
people aware of research-driven progress is incredibly
important to me.”
“I’m proud to help Stand Up To Cancer and
their supporter Lilly Oncology raise awareness for
colorectal cancer,” said award-winning actor Kinnear.
“Through this PSA campaign, we want people to realize they
are their most powerful advocates. If diagnosed with
colorectal cancer, it is important to ask questions, be
informed and to know the makeup of your tumor to help you
and your doctor decide on the best possible treatment.”
“We’re honored to have Greg Kinnear join
Stand Up To Cancer and our collaborator Lilly Oncology in
bringing attention to this critical initiative,” said Lisa
Paulsen, co-founder of Stand Up To Cancer and CEO of the
Entertainment Industry Foundation. “With the progress being
made in cancer research and the capability to personalize
your treatment, patients have to be armed with the right
information to make smart decisions regarding their
treatment choices.”
“Lilly Oncology is excited to be part of this
important initiative, helping to educate and empower people
with CRC to get their tumor tested, which can lead to a
treatment plan that’s right for them,” said Newt Crenshaw,
vice president of Lilly Oncology.
Lilly Oncology has also teamed up with four
colorectal cancer patient advocacy groups to further spread
the word. They are: Colon
Cancer Alliance, Fight
Colorectal Cancer, Michael’s
Mission and Susie’s
Cause.
To learn more, visit www.standup2cancer.org/colorectalcancer.
To join the conversation, like us on Facebook at @StandUpToCancer or
follow us on Twitter at @SU2C and
use #testyourtumor.
# # #
About
Stand Up To Cancer
Stand Up To Cancer (SU2C) raises funds to
accelerate the pace of research to get new therapies to
patients quickly and save lives now. SU2C, a program of the
Entertainment Industry Foundation (EIF), a 501(c)(3)
charitable organization, was established in 2008 by film and
media leaders who utilize the industry’s resources to engage
the public in supporting a new, collaborative model of
cancer research, and to increase awareness about progress
being made in the fight against the disease. As SU2C’s
scientific partner, the American Association for Cancer
Research (AACR) and a Scientific Advisory Committee led by
Nobel Laureate Phillip A. Sharp, Ph.D., conduct rigorous,
competitive review processes to identify the best research
proposals to recommend for funding, oversee grants
administration, and provide expert review of research
progress.
For more information on Stand Up To Cancer,
visit www.standup2cancer.org.
About
Lilly Oncology
For more than fifty years, Lilly has been
dedicated to delivering life-changing medicines and support
to people living with cancer and those who care for them.
Lilly is determined to build on this heritage and continue
making life better for all those affected by cancer around
the world. To learn more about Lilly's commitment to people
with cancer, please
visit www.LillyOncology.com
About Eli
Lilly and Company
Lilly is a global healthcare
leader that unites caring with discovery to make life better
for people around the world. We were founded more than a
century ago by a man committed to creating high-quality
medicines that meet real needs, and today we remain true to
that mission in all our work. Across the globe, Lilly
employees work to discover and bring life-changing medicines
to those who need them, improve the understanding and
management of disease, and give back to communities through
philanthropy and volunteerism. To learn more about Lilly,
please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.
|